시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
단순포진바이러스 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 바이러스 유형별, 치료법별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Herpes Simplex Virus Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Virus Type, By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2020-2030F
상품코드 : 1779034
리서치사 : TechSci Research
발행일 : 2025년 07월
페이지 정보 : 영문 188 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,500 ￦ 6,561,000
Unprintable PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.
US $ 5,500 ￦ 8,019,000
PDF and Excel (Multi-User License) help
PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.
US $ 8,000 ￦ 11,664,000
PDF and Excel (Custom Research License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

단순포진바이러스(HSV) 치료 세계 시장은 2024년에 25억 2,000만 달러로 평가되었으며, 예측 기간 동안 CAGR 8.05%로 2030년에는 39억 8,000만 달러에 달할 것으로 예측됩니다.

세계 단순포진바이러스(HSV) 치료 시장은 제약 및 헬스케어 산업 중에서도 HSV 감염의 지속적인 세계적 유행에 힘입어 역동적으로 발전하고 있는 분야입니다. HSV는 주로 입술 헤르페스와 생식기 헤르페스의 원인으로 알려져 있지만, 평생에 걸쳐 감염되는 특성, 주기적인 발생, 잠재적인 합병증으로 인해 공중 보건에 심각한 우려를 낳고 있습니다. 인지도와 진단율이 높아짐에 따라 효과적인 치료에 대한 수요는 계속 증가하고 있습니다. 예를 들어, 단순포진바이러스(HSV) 감염의 유병률은 전 세계적으로 증가하고 있습니다. WHO는 2023년 4월 현재 50세 미만 약 37억 명(인구의 약 67%)이 HSV-1에 감염되어 있고, 15-49세 약 4억 9,100만 명이 HSV-2에 감염된 것으로 추정하고 있습니다. 이러한 높은 감염률은 효과적인 치료 관리의 필요성을 강조하고 있습니다. HSV의 치료 옵션은 주로 항바이러스제이며, 결정적인 치료를 제공하기보다는 심각성과 발생 빈도를 감소시키기 위해 고안된 것입니다. 이러한 항바이러스 치료는 증상을 관리하고 감염 위험을 낮추며 환자의 삶의 질을 개선하는 데 도움이 됩니다. 시중에는 아시클로버, 바라시시비르, 팜시시비르 등 경구용 항바이러스제를 포함한 다양한 확립된 약물이 사용되고 있으며, 이들 약제는 그 효과와 안전성이 입증되어 표준 치료법으로 자리 잡았습니다. 이 외에도 현재 진행 중인 연구에서는 치료 성과와 환자 순응도를 개선하기 위해 새로운 항바이러스제와 새로운 약물전달 시스템을 연구하고 있습니다. 기존 의약품과 더불어 대체요법 및 보조요법에 대한 관심도 높아지고 있습니다. 여기에는 기존의 항바이러스제를 보완하기 위한 국소 크림, 면역요법, 자연 요법 등이 포함됩니다. 분자생물학과 바이러스학의 발전은 백신과 유전자 치료제의 개발을 촉진하고 있으며, 이는 HSV에 대한 미래 예방 및 치료 전략으로 유망합니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 25억 2,000만 달러
시장 규모 : 2030년 39억 8,000만 달러
CAGR : 2025-2030년 8.05%
급성장 부문 의약품
최대 시장 북미

시장 촉진요인

HSV 감염의 높은 유병률과 재발률

주요 시장 과제

의료 접근성 및 인프라의 불안정성

주요 시장 동향

진단 혁신의 성장

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 임상시험 분석

제6장 단순포진바이러스(HSV) 치료 세계 시장 전망

제7장 북미의 단순포진바이러스(HSV) 치료 시장 전망

제8장 유럽의 단순포진바이러스(HSV) 치료 시장 전망

제9장 아시아태평양의 단순포진바이러스(HSV) 치료 시장 전망

제10장 남미의 단순포진바이러스(HSV) 치료 시장 전망

제11장 중동 및 아프리카의 단순포진바이러스(HSV) 치료 시장 전망

제12장 시장 역학

제13장 시장 동향과 발전

제14장 경쟁 구도

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm
영문 목차

영문목차

Global Herpes Simplex Virus (HSV) Treatment Market was valued at USD 2.52 billion in 2024 and is expected to reach USD 3.98 billion by 2030 with a CAGR of 8.05% during the forecast period. The Global Herpes Simplex Virus (HSV) Treatment Market is a dynamic and evolving sector within the pharmaceutical and healthcare industries, driven by the persistent prevalence of HSV infections worldwide. HSV, primarily known for causing oral and genital herpes, remains a significant public health concern due to its lifelong nature, periodic outbreaks, and potential complications. As awareness and diagnosis rates improve, the demand for effective treatments continues to grow. For instance, the prevalence of herpes simplex virus (HSV) infection is increasing globally. As of April 2023, WHO estimates that approximately 3.7 billion people under 50-about 67% of the population-live with HSV-1, while around 491 million individuals aged 15 to 49 are infected with HSV-2. This high infection rate underscores the critical need for effective therapeutic management. Treatment options for HSV primarily focus on antiviral medications designed to reduce the severity and frequency of outbreaks rather than offering a definitive cure. These antiviral therapies help manage symptoms, lower transmission risks, and improve the quality of life for patients. The market features a variety of established drugs, including oral antivirals like acyclovir, valacyclovir, and famciclovir, which have become standard treatments due to their proven efficacy and safety profiles. Alongside these, ongoing research is exploring new antiviral agents and novel drug delivery systems to enhance treatment outcomes and patient compliance. In addition to traditional pharmaceuticals, the market is witnessing an increase in interest towards alternative and adjunct therapies. These include topical creams, immunotherapies, and natural remedies aimed at complementing conventional antiviral drugs. Advances in molecular biology and virology are fostering the development of vaccines and gene therapies, which hold promise for future preventive and therapeutic strategies against HSV.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.52 Billion
Market Size 2030USD 3.98 Billion
CAGR 2025-20308.05%
Fastest Growing SegmentDrugs
Largest MarketNorth America

Key Market Drivers

High Prevalence and Recurrence of HSV Infections

The high prevalence and recurrence of Herpes Simplex Virus (HSV) infections play a critical role in shaping the global treatment market. For instance, in September 2022, researchers at Fred Hutchinson Cancer Center discovered a potential herpes cure using gene therapy. Their experimental treatment successfully targeted latent infections in animals, reducing viral activity and significantly suppressing transmission rates to other animals. This breakthrough offers promising advancements toward more effective HSV treatments and possible long-term solutions.

HSV is one of the most common viral infections worldwide, with a large portion of the population infected, often unknowingly. This widespread prevalence creates a steady and ongoing demand for treatment options. Many individuals experience periodic outbreaks throughout their lives, as the virus remains dormant in nerve cells and can reactivate under certain conditions such as stress or weakened immunity. The recurrent nature of HSV infections means patients frequently require long-term management rather than a one-time treatment. This need drives continuous consumption of antiviral medications that help control symptoms and reduce the frequency of outbreaks. The persistent presence of HSV in a significant segment of the population ensures sustained demand for both episodic and suppressive therapies. Episodic treatment focuses on reducing the severity and duration of outbreaks when they occur, while suppressive treatment aims to prevent or minimize recurrence, offering patients greater control over their condition. Healthcare providers recognize the importance of managing recurrent HSV infections to reduce transmission risks and improve patients' quality of life. This recognition encourages ongoing prescriptions and innovations in antiviral drugs and formulations that provide better efficacy, safety, and convenience. The repeated need for treatment creates a stable and growing market, encouraging pharmaceutical companies to invest in research and development of newer therapies. The combination of a large infected population and frequent recurrence ensures the HSV treatment market remains robust, with continued opportunities for expanding access and improving treatment options worldwide.

Key Market Challenges

Variability in healthcare access and infrastructure

Variability in healthcare access and infrastructure presents a significant challenge for the Global Herpes Simplex Virus (HSV) Treatment Market. In many regions, especially low- and middle-income countries, limited healthcare resources restrict the availability of diagnostic tools and antiviral medications essential for effective HSV management. This disparity leads to underdiagnosis and undertreatment of HSV infections, despite their widespread prevalence. Access to reliable laboratory facilities capable of performing accurate HSV testing is often inadequate in underserved areas. Without proper diagnosis, many patients remain unaware of their infection status, which hinders timely treatment and increases the risk of transmission. The lack of trained healthcare professionals who can provide counseling and prescribe appropriate therapies further limits effective management. Economic constraints also affect patients' ability to afford ongoing antiviral treatments. In regions with limited healthcare funding or out-of-pocket payment systems, many individuals may forgo treatment due to cost, which suppresses market growth. In contrast, developed countries with advanced healthcare infrastructure offer better access to diagnostics and a wider range of treatment options, driving higher market demand. The variability in healthcare systems across countries creates challenges for pharmaceutical companies attempting to establish a uniform market strategy. Regulatory environments, reimbursement policies, and distribution networks differ greatly, affecting how easily treatments reach patients. Companies must adapt to local conditions, which can increase operational complexity and costs.

Improving healthcare infrastructure and access is critical to expanding the HSV treatment market globally. Efforts to enhance diagnostic capabilities, affordability, and healthcare provider training are essential to ensure patients in all regions can receive timely and effective treatment.

Key Market Trends

Growth in diagnostic innovations

Growth in diagnostic innovations plays a crucial role in shaping the Global Herpes Simplex Virus (HSV) Treatment Market by enabling earlier and more accurate detection of infections. Advanced diagnostic technologies have improved the ability of healthcare providers to identify HSV even in asymptomatic patients, which expands the pool of individuals seeking treatment. Early diagnosis is essential for timely intervention, reducing transmission rates, and improving patient outcomes. Modern diagnostic tools such as polymerase chain reaction (PCR) assays offer high sensitivity and specificity compared to traditional methods. These molecular techniques allow for rapid detection of viral DNA, enabling clinicians to distinguish between HSV-1 and HSV-2 types. Type-specific diagnosis is important because it informs treatment decisions and counseling regarding disease prognosis and transmission risks. Point-of-care testing devices are becoming more widely available, facilitating diagnosis in various clinical settings without the need for complex laboratory infrastructure. Serological tests have also improved, providing better accuracy in detecting antibodies to HSV. These developments help identify individuals with latent infections who may benefit from suppressive therapy. The availability of more reliable and user-friendly tests encourages routine screening, particularly in populations at higher risk for HSV infections.

Improved diagnostics drive market growth by increasing the number of diagnosed cases requiring treatment. Pharmaceutical companies benefit from this trend as heightened detection rates translate into greater demand for antiviral drugs. Laboratories and diagnostic companies are investing in developing faster, cheaper, and more accessible tests to meet growing clinical needs. Enhanced diagnostics support personalized treatment approaches, allowing healthcare providers to tailor therapies based on infection status and type. This trend is integral to expanding the overall HSV treatment market worldwide.

Key Market Players

Report Scope:

In this report, the Global Herpes Simplex Virus (HSV) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herpes Simplex Virus (HSV) Treatment Market, By Virus Type:

Herpes Simplex Virus (HSV) Treatment Market, By Treatment:

Herpes Simplex Virus (HSV) Treatment Market, By Route of Administration:

Herpes Simplex Virus (HSV) Treatment Market, By Distribution Channel:

Herpes Simplex Virus (HSV) Treatment Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herpes Simplex Virus (HSV) Treatment Market.

Available Customizations:

Global Herpes Simplex Virus (HSV) Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Clinical Trial Analysis

6. Global Herpes Simplex Virus (HSV) Treatment Market Outlook

7. North America Herpes Simplex Virus (HSV) Treatment Market Outlook

8. Europe Herpes Simplex Virus (HSV) Treatment Market Outlook

9. Asia-Pacific Herpes Simplex Virus (HSV) Treatment Market Outlook

10. South America Herpes Simplex Virus (HSV) Treatment Market Outlook

11. Middle East and Africa Herpes Simplex Virus (HSV) Treatment Market Outlook

12. Market Dynamics

13. Market Trends & Developments

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기